Literature DB >> 16981011

Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model.

Zhigang Yu1, Nahid Dadgar, Megan Albertelli, Kirsten Gruis, Cynthia Jordan, Diane M Robins, Andrew P Lieberman.   

Abstract

Kennedy disease, a degenerative disorder characterized by androgen-dependent neuromuscular weakness, is caused by a CAG/glutamine tract expansion in the androgen receptor (Ar) gene. We developed a mouse model of Kennedy disease, using gene targeting to convert mouse androgen receptor (AR) to human sequence while introducing 113 glutamines. AR113Q mice developed hormone and glutamine length-dependent neuromuscular weakness characterized by the early occurrence of myopathic and neurogenic skeletal muscle pathology and by the late development of neuronal intranuclear inclusions in spinal neurons. AR113Q males unexpectedly died at 2-4 months. We show that this androgen-dependent death reflects decreased expression of skeletal muscle chloride channel 1 (CLCN1) and the skeletal muscle sodium channel alpha-subunit, resulting in myotonic discharges in skeletal muscle of the lower urinary tract. AR113Q limb muscles show similar myopathic features and express decreased levels of mRNAs encoding neurotrophin-4 and glial cell line-derived neurotrophic factor. These data define an important myopathic contribution to the Kennedy disease phenotype and suggest a role for muscle in non-cell autonomous toxicity of lower motor neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981011      PMCID: PMC1564432          DOI: 10.1172/JCI28773

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport.

Authors:  Gerardo Morfini; Gustavo Pigino; Györgyi Szebenyi; Yimei You; Sarah Pollema; Scott T Brady
Journal:  Nat Neurosci       Date:  2006-06-04       Impact factor: 24.884

2.  Gene expression in Huntington's disease skeletal muscle: a potential biomarker.

Authors:  Andrew D Strand; Aaron K Aragaki; Dennis Shaw; Thomas Bird; Janice Holton; Christopher Turner; Stephen J Tapscott; Sarah J Tabrizi; Anthony H Schapira; Charles Kooperberg; James M Olson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

3.  Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice.

Authors:  Xiaofeng Gu; Chenjian Li; Weizheng Wei; Victor Lo; Shiaoching Gong; Shi-Hua Li; Takuji Iwasato; Shigeyoshi Itohara; Xiao-Jiang Li; Istvan Mody; Nathaniel Heintz; X William Yang
Journal:  Neuron       Date:  2005-05-05       Impact factor: 17.173

4.  Onset and progression in inherited ALS determined by motor neurons and microglia.

Authors:  Séverine Boillée; Koji Yamanaka; Christian S Lobsiger; Neal G Copeland; Nancy A Jenkins; George Kassiotis; George Kollias; Don W Cleveland
Journal:  Science       Date:  2006-06-02       Impact factor: 47.728

5.  Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression.

Authors:  Alexandre Méjat; Francis Ramond; Rhonda Bassel-Duby; Saadi Khochbin; Eric N Olson; Laurent Schaeffer
Journal:  Nat Neurosci       Date:  2005-02-13       Impact factor: 24.884

6.  Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction.

Authors:  Monzy Thomas; Jennifer M Harrell; Yoshihiro Morishima; Hwei-Ming Peng; William B Pratt; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2006-04-27       Impact factor: 6.150

7.  Comparison of gene expression of 2-mo denervated, 2-mo stimulated-denervated, and control rat skeletal muscles.

Authors:  Tatiana Y Kostrominova; Douglas E Dow; Robert G Dennis; Richard A Miller; John A Faulkner
Journal:  Physiol Genomics       Date:  2005-04-19       Impact factor: 3.107

8.  Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice.

Authors:  Megan A Albertelli; Arno Scheller; Michele Brogley; Diane M Robins
Journal:  Mol Endocrinol       Date:  2006-04-06

9.  Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein.

Authors:  Zhigang Yu; Nahid Dadgar; Megan Albertelli; Arno Scheller; Roger L Albin; Diane M Robins; Andrew P Lieberman
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

Review 10.  Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA).

Authors:  Masahisa Katsuno; Hiroaki Adachi; Masahiro Waza; Haruhiko Banno; Keisuke Suzuki; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  Exp Neurol       Date:  2006-03-02       Impact factor: 5.330

View more
  90 in total

Review 1.  Therapeutic approaches to spinal and bulbar muscular atrophy.

Authors:  Srikanth Ranganathan; Kenneth H Fischbeck
Journal:  Trends Pharmacol Sci       Date:  2010-09-20       Impact factor: 14.819

2.  Contractile dysfunction in muscle may underlie androgen-dependent motor dysfunction in spinal bulbar muscular atrophy.

Authors:  Kentaro Oki; Katherine Halievski; Laura Vicente; Youfen Xu; Donald Zeolla; Jessica Poort; Masahisa Katsuno; Hiroaki Adachi; Gen Sobue; Robert W Wiseman; S Marc Breedlove; Cynthia L Jordan
Journal:  J Appl Physiol (1985)       Date:  2015-02-05

Review 3.  Genetic approaches to the treatment of inherited neuromuscular diseases.

Authors:  Bhavya Ravi; Anthony Antonellis; Charlotte J Sumner; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

4.  Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy.

Authors:  Jamie A Johansen; Zhigang Yu; Kaiguo Mo; D Ashley Monks; Andrew P Lieberman; S Marc Breedlove; Cynthia L Jordan
Journal:  Neurobiol Dis       Date:  2008-12-31       Impact factor: 5.996

5.  Androgens in health and disease: an overview.

Authors:  Cynthia L Jordan; Lydia Doncarlos
Journal:  Horm Behav       Date:  2008-03-06       Impact factor: 3.587

Review 6.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

7.  Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease.

Authors:  Douglas Ashley Monks; Jamie A Johansen; Kaiguo Mo; Pengcheng Rao; Bryn Eagleson; Zhigang Yu; Andrew P Lieberman; S Marc Breedlove; Cynthia L Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-02       Impact factor: 11.205

8.  The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.

Authors:  Andrew P Lieberman; Diane M Robins
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

Review 9.  In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Pennuto; Manuela Basso
Journal:  J Mol Neurosci       Date:  2015-11-27       Impact factor: 3.444

Review 10.  Targeted Molecular Therapies for SBMA.

Authors:  Carlo Rinaldi; Bilal Malik; Linda Greensmith
Journal:  J Mol Neurosci       Date:  2015-11-17       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.